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ABSTRACT
INTRACRANIAL INFUSIONS OF NEUROTENSIN AGONISTS PRODUCE AN
ANXIOLYTIC PROFILE IN A RAT ULTRASONIC VOCALIZATION MODEL
By
Floyd F. Steele III
Neurotensin (NT) is a peptide neurotransmitter that interacts with brain
monoamine neurotransmitter systems. It has been demonstrated that neurotensin type 1
and type 2 receptor agonists influence animal models of psychological disorders and pain
regulation, respectively. It has already been shown that the systemic administration of the
selective neurotensin type 1 receptor agonist PD149163 can attenuate the number of fearinduced 22-kHz ultrasonic vocalizations (USVs) produced by male Wistar rats. A
reduction in the number of 22-kHz USV calls is indicative of an anxiolytic effect. The
current study used a USV model to evaluate the effects of PD149163 (0.1, 1.0, and 10.0
ng) and endogenous NT (0.1, 1.0, and 10.0 µg) when administered into the lateral
ventricle of male Wistar rats. Both 10ng of PD149163 and 10µg of NT were shown to
attenuate USV calls when administered into the lateral ventricle. PD149163 was found to
have a higher potency than NT in the USV model. In addition, while 100ng of PD149163
significantly reduced USV calls, it did not reduce locomotion on an open field that was
surrounded by bright lighting. These data suggest neurotensin receptor activation is a
putative mechanism for novel pharmacological treatments of anxiety disorders.
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INTRODUCTION

Anxiety and Panic
Anxiety disorders are associated with attentional deficits, physical tension,
restlessness, irritability, panic, phobia, and social isolation. While anxiety disorder
subtypes can vary in symptomology, e.g. separation anxiety disorder, agoraphobia and
specific phobia disorder, other anxiety disorders, such as Generalized Anxiety Disorder
(GAD) versus Panic Disorder, differ in symptom intensity and duration (American
Psychiatric Association, 2013). A comorbidity of no less than 50% has been found
between anxiety disorders and major depressive disorder, and around 30% of United
States citizens suffer from an anxiety disorder at least once in their lifetime (Hirschfeld,
2001).
Anxiety disorders can be comprised of acute/intense panic attack episodes which
are correlated with hyperactivity of the sympathetic nervous system; this hyperactivity
can result in tachycardia and hyperventilation. The current Diagnostic and Statistical
Manual of Mental Disorders, DSM-5, states that panic attack symptoms can be used to
predict the severity, course and treatment of all other anxiety disorders, as well as
psychological disorders not classified as anxiety disorders (American Psychiatric
Association, 2013). The symptoms of panic attacks can be represented using animal
models of panic responding. This panic responding can be elicited by both isolatable
stimuli and environmental contexts.
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Molecular Basis and Pharmacological Treatments of Anxiety
There is evidence that elevated activity of the sympathetic nervous system (SNS),
which is mediated by noradrenergic neurotransmission, is a product of central nervous
system (CNS) chemical signaling abnormalities. It has been demonstrated that the α2adrenoceptor antagonist yohimbine only evokes panic attacks for individuals who have
been diagnosed with panic disorder (Nutt et al., 1998). This suggests that blocking α2adrenergic receptors is an insufficient means of producing panic attacks. It follows that,
while anxiety is sometimes treated by peripherally acting β-adrenergic antagonists, most
modern anxiolytic agents target CNS systems that mediate peripheral adrenaline levels
(Sinclair & Nutt, 2007).
While many CNS neurotransmitter systems have been linked to anxiety, e.g.
dopaminergic D1 and D2 receptors, glutamatergic AMPA and NMDA receptors, and
CCKB receptors of the neuropeptide cholecystokinin, all currently marketed anxiolytic
medications either modulate GABAA receptors or block the reuptake of presynaptic
serotonin (Dooley & Klamt, 1993; Jessa et al., 1996; Simon et al., 1993; Nutt,
2005).Benzodiazepine (BDZ) drugs bind to the BDZ site on GABAA receptors,
potentiating the inhibitory influx of chloride that is initiated by GABAA receptor
agonists. Since the GABAA receptor is the primary inhibitory receptor in the CNS, BDZs
such as diazepam (Valium) and alprazolam (Xanax) indirectly treat anxiety by inhibiting
other neurotransmitter systems that are associated with anxiety (Sinclair & Nutt, 2007).
BDZs are often used to treat extreme cases of panic disorder, but are not the first
line of treatment since, like most CNS depressants, they produce a risk of drug
dependence when chronically administered (Licata & Rowlett, 2008). A withdraw
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induced increase in baseline anxiety has occurred in almost a quarter of individuals who
have chronically taken BDZs, and while on a BDZ, a person may become drowsy and
experience motor coordination deficits (Kaplan & DuPont, 2005).
The first line of treatment for most anxiety disorders is the use of selective
serotonin reuptake inhibitors (SSRIs), e.g. fluoxetine (Prozac) and sertraline (Zoloft),
which are also the most common treatments for depressive disorders (Bystritsky et al.,
2013). Since SSRIs increase synaptic serotonin (5-HT) levels by inhibiting reuptake of 5HT from the synaptic cleft, brain functional abnormalities resulting in the inability of
serotonergic neurons to produce and/or secrete 5-HT may be important factors in the
pathology of anxiety disorders. While SSRIs act by blocking the activity of 5-HT
transporter (SERT), SERT knockout mice, which display elevated synaptic 5-HT
concentrations, demonstrate an anxiogenic behavioral phenotype when compared to mice
that express SERT (Kalueff et al., 2007). This suggests that there are therapeutic
limitations to fully blocking SERT at certain brain regions.
Pre- and postsynaptic serotonin 5-HT1A receptor expression may also influence
anxiety. Humans with lower densities of CNS 5-HT1A receptors demonstrate more
symptoms of anxiety than those expressing the average density (Condren et al., 2002).
Additionally, Gross et al. (2002) showed, while raphe nucleus 5-HT1A autoreceptor
knockout mice don’t exhibit an anxiogenic phenotype, whole brain 5-HT1A receptor
knockout mice do. This means that forebrain 5-HT1A receptor activation can influence
anxiety-like behavior independently of raphe nucleus 5-HT1A activation (Gross et al.,
2002). Similar to GABAA receptor activation, postsynaptic 5-HT1A activation is known
to inhibit both limbic and cortical glutamate transmission. Postsynaptic 5-HT1A activation
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enhances potassium efflux and reduces adenylyl cyclase activity in postsynaptic
glutamatergic neurons (Millan, 2003). Unlike GABAA activation, 5-HT1A activation is
not associated with memory deficits. When on diazepam, human subjects with GAD have
been shown to exhibit deficits in memory recall after a 20 minute delay; buspirone, a
selective serotonin 5-HT1A receptor partial agonist, does not produce these deficits (Lucki
et al., 1987).
Administration of 5-HT1A receptor agonists and SSRIs have been found to
produce aversive effects in humans during initial treatment. The symptoms include
nausea, motor deficits and depressive symptoms such as thoughts of suicide (Nutt, 2005).
These aversive effects are correlated with activation of both the hypothalamocorticotropic axis and sympathetic noradrenergic activity, suggesting that an acute
increase in serotonergic neurotransmission up-regulates stress mechanisms (Millan,
2003). After the onset of treatment, anxiety symptoms often dissipate, supporting the
theory that desensitization of brain 5-HT1A autoreceptors and increased expression of
forebrain postsynaptic 5-HT1A receptors mediate the delayed efficacy of SSRIs. Le Poul
et al. (1995) showed that after 3 days of daily SSRI treatment, rats demonstrated
desensitization of somatodendritic 5-HT1A autoreceptors in their dorsal raphe nuclei.
Briones-Aranda, Rocha & Picazo (2005) found that mice expressed a greater density of
amygdala 5-HT1A receptors after experiencing a forced-swim procedure. SSRIs are not
without additional side effects. Prolonged SSRI treatment can result in asthenia,
unhealthy eating habits and sexual dysfunction (Nutt, 2005; Hirschfeld, 2003).
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Subcortical Circuitry and Animal Models of Fear and Anxiety
Fear is the activation of multiple brain systems that promote defensive behavior;
at healthy levels, fear responding is used to increase the fitness of a species (Fendt and
Fanselow, 1999). Using rodent models, unconditioned fear can be studied by measuring a
rodent’s tendency to burrow, defecate, explore novel environments, interact with novel
objects, hide in confined spaces, move near walls, and startle. Rodent models of anxiety
are also used to study conditioned fear, e.g. conditioned freezing, fear-potentiated startle
and ultrasonic vocalizations. Models of conditioned and unconditioned fear have been
used to uncover some of what is currently known about the mechanisms of effective
anxiolytic agents and their connection to subcortical circuitry.
There is direct evidence that the amygdala is a locus for the mediation of fear. In
the fear-potentiated startle paradigm, a model that measures an increase in startle that is
provoked by an external cue, potentiated startle is blocked when lesions are made in the
amygdala (Hitchcock & Davis, 1986). Microinjections of the glutamatergic NMDA
receptor antagonists AP-5 and AP-7 have been shown to block the acquisition of fear
potentiated startle when injected into the basolateral amygdala, with AP-5 also blocking
fear extinction (Campeau et al., 1992; Falls et al., 1992). Similarly, NMDA antagonism at
the basolateral amygdala disrupts CS-US pairing in contextual freezing paradigms using
rats (Fanselow & Kim, 1994). While these compounds blocked CS-US learning, they did
not block the expression of fear-potentiated startle when they were administered after the
completion of acquisition trials. The amygdala is also involved in the expression of fear.
Microinjections of glutamatergic AMPA receptor antagonists block the expression of
fear-potentiated startle when injected non-selectively into the amygdala; an effect that is
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not produced by NMDA antagonists (Walker & Davis, 1997). Cholecystokinin CCKB
receptor activation has also been shown to increase the expression of startle when
injected into the amygdala (Frankland et al., 1997).
The amygdala, while morphologically subdivided into about 6 sub-regions, is
more often functionally subdivided into the basolateral complex of the amygdala (BLA)
and the central complex of the amygdala (CeA). The current theory of amygdaloid fear
processing is that the activated BLA, after receiving input from the thalamus and cortical
structures, uses glutamatergic transmission to activate the amygdala’s intercalated
paracapsular islands (Royer et al., 1999). Activation of the GABAergic neurons of the
lateral islands locally inhibits the medial paracapsular inhibitory GABAergic neurons
(Ehrlich et al., 2009). Since the medial islands project onto the CeA, the intercalated
paracapsular islands act as a feed-forward disinhibitory system that links the BLA to the
CeA. This suggests that amygdala circuitry is dense with GABAergic gating
mechanisms.
A diversity of GABAergic neurons has been located in the BLA as well as other
parts of the amygdala. Bienvenu et al. (2012) reported that, when using a parvalbumin
marker in rat BLA tissue, two functionally different GABAergic neuron subtypes were
located. There are “basket” interneurons that are involved in feed-forward inhibition; they
project to the soma and proximal dendrites of amygdaloid pyramidal cells. There are also
interneurons that form axo-axonic synapses with BLA pyramidal cells, suggesting an
additional feed-back inhibitory mechanism. There are GABAergic interneurons in the
BLA that express both cannabinoid CB1 autoreceptors and CCKB receptors; this supports
the notion that CCKB receptors modulate the activity of GABA neurons. Microinjection
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of CCK potentiates GABAergic inhibition of neurons within the amygdala by activating
CCKB receptors (Branchereau et al., 1992; McDonald & Mascagni, 2001).
Behavioral paradigms have also been used to show the importance of GABAergic
transmission in fear learning. Zangrossi and Graeff (1994) demonstrated that bilateral
injection of the BDZ agonist midazolam in the rat BLA increases the amount of time a rat
spends exploring the open arms of an elevated plus maze; behavior predictive of
anxiolytic drug effects. The 5-HT1A full agonist 8-OH-DPAT did not increase time spent
exploring the open arms in this study. It was also found that 5-HT2 antagonism made the
animals exhibit anxiogenic behavior.
Heldt et al. (2012) found that viral disruption of glutamic acid decarboxylase 67
(GAD67) expression produces both a deficit in fear extinction and in the ability of
diazepam to reduce conditioned freezing in C57BL\6 mice. The viral vectors were
bilaterally microinjected into the amygdala; reduced freezing to an auditory cue
correlated with fewer GAD67 enzymes within the amygdala. GAD67 metabolizes Lglutamic acid (glutamate) into GABA. BDZs show differential efficacy depending on
which region of the amygdala they are administered. When midazolam is administered to
the CeA, it produces a reduction in the passive avoidance of pain-eliciting stimuli (i.e.
probe burying task), without reducing time spent in closed arms on the elevated-plus
maze (EPM) (Pesold & Treit, 1995). Conversely, microinjections of midazolam into the
BLA increases time spent on EPM open arms while having no effect on pain-related
passive avoidance.
A human study conducted by Lucki et al. (1987) looked at 37 patients diagnosed
with GAD. It was determined that, compared to vehicle, patients given 5 mg/kg of
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diazepam were able to remember fewer terms after a 20 minute delay in the free recall
task. The 5-HT1A partial agonist buspirone did not produce this deficit at either 5 or 10
mg/kg. This highlights the importance of elucidating the roles of amygdala and hindbrain
serotonergic systems in the modulation of anxiety. Using a trace conditioning paradigm,
Zhang et al. (2013) used 1 mg/kg of the 5-HT2A agonist TCB-2 to increase the rate of fear
extinction. It was also confirmed that 0.5 mg/kg of MDL 11,939, a 5-HT2A antagonist,
can be used to delay the onset of extinction. An electrophysiological study by Hammock
et al. (2009) used the patch-clamp technique to study the role of serotonergic systems in
the bed nucleus of the stria terminalis (BNST), a major output from the amygdala to the
thalamus. While BNST serotonergic systems consist of multiple 5-HT subtypes (e.g. 5HT1A, 5-HT2A, 5-HT2C, etc.), it is the inhibitory effect of 5-HT that reduces anxiogenic
activity associated with BNST excitation.
Vecente and Zangrossi (2012) used fluoxetine and imipramine to show that 5HT2C receptors of the BLA have a facilitating role in anxiety. 5-HT2C activation led to an
increase in inhibitory avoidance learning in the elevated T-maze paradigm. Strauss et al.
(2013) used the elevated T-maze to show that BLA 5-HT1A has the opposite effect; both
0.4 and 16 nmol of 8-OH-DPAT reduce the acquisition of both inhibitory avoidance and
escape behaviors. Additionally, these concentrations produce anxiolytic effects on both
the light-dark transition model and the Vogel conflict test; a greater amount of time was
spent in the light compartment and more punished drinking was observed, respectively.
These results were confirmed using microinjections of 0.37 nmol WAY-100635 and 1040 nmol mitazolam to block and reverse the effects, respectively.
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Dopamine (DA) also has a role in regulating anxiety and anxiety-like behavior in
non-human animals. When placed in an open field, mice that are given non-selective
dopamine D1 and D2 agonists exhibit an increase in thigmotaxis, suggesting that
dopaminergic mechanisms might allow for novel anxiety treatments (Simon et al., 1994).
Bartoszyk (1998) found that many dopamine D2 receptor agonists (e.g. quinpirole,
apomorphine, etc.) reduce 22-kHz ultrasonic vocalizations in male Sprague Dawley rats.
Rat 22-kHz ultrasonic vocalizations (USVs) are used as a measure of negative affect and
will be discussed in more detail in another section. Facilitation of dopamine D2
autoreceptors has been demonstrated to reduce USV production in conditioned foot-stock
paradigms and many of the effective dopaminergic compounds administered in Bartoszyk
(1998) were selective dopamine D2-family autoreceptor agonists (e.g. pramipexole,
roxindole, 7-OH-DPAT, etc.). While a reduction in dopaminergic transmission may
directly influence the expression of USVs, there is evidence that the dopamine D2 agonist
apomorphine reduces burying behavior in the Vogel conflict task and increases
exploratory behavior (Hjorth et al., 1987; Talalaenko et al., 1994).
Systemic injections of dopamine D1 agonist SKF 38393, D1 antagonist SCH
23390, D2 agonist quinpirole, and D2 antagonist sulpride do not influence the acquisition
of conditioned fear in fear-potentiated startle and conditioned freezing tasks (Ribeiro de
Oliveira et al., 2006). After the acquisition phase of the fear-potentiated startle and
conditioned freezing tasks, the dopamine D2 agonist quinpirole (0.1 and 0.25 mg/kg)
reduced startle magnitude and freezing, respectively. These doses did not decrease
locomotor activity in the open field task, suggesting that dopamine D2 receptor activity
modulates the expression of both learned and unlearned fear. Contrarily, amygdaloid
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microinjections of the selective dopamine D1 antagonist SCH 23390 blocks the
acquisition of fear potentiated startle, conditioned freezing and second-order conditioning
(Lamont & Kokkinidis, 1998; Guarraci et al., 1999; Nader & LeDoux, 1999). While there
is not an amount of SCH 23390 that has been shown to attenuate the expression of
learned fear on the aforementioned models, Parez del la Mora et al. (2005) has shown
that when SCH 23390 is microinjected into the BLA and intercalated islands, rats show
an increase in time spent in the illuminated box of a White and Black Box test. Dopamine
D1 receptor antagonism can suppress unconditioned fear.
Intra-amygdaloid injections of dopamine D2 receptor antagonists tend to show
differential effects across animal models of fear. Ralcopride (2-8 μg) blocks the
acquisition of fear potentiated startle when injected into the BLA, while smaller
quantities of raclopride (0.73 and 2.4 μg) are injected into the CeA, rats exhibit an
anxiogenic effect on the Shock-Probe Burying test (Greba et al., 2001). Another
dopamine D2 receptor antagonist, eticopride, has been shown to block the acquisition of
freezing when a 1 μg injection is placed into the CeA (Guarraci et al., 2000). While
dopamine D2 receptor antagonism may potentiate the behavioral markers of
unconditioned fear, it can attenuate the formation of conditioned fear. Bissiere et al.
(2003) demonstrated that the lateral amygdala (LA) dopamine system is a gating
mechanism for LA long-term potentiation (LTP). The in vitro conjunction of thalamic
afferent presynaptic stimulation, postsynaptic LA stimulation and DA administration was
found to induce LA LTP only when the LA GABAergic system was functional. When
100μM picrotoxin, a GABAA antagonist, and 100μM DA were administered into the LA,
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DA did not induce LA LTP. Quinpirole, a dopamine D2 receptor agonist, was used to
facilitate the effect of the combined treatment.
Ponnusamy et al. (2005) showed, in mice, that the dopamine D2 receptor agonist
quinpirole blocked fear extinction when systemically injected prior to the extinction
phase of a cued footstock paradigm. After three pairings of white noise and shock, they
either injected rats with quinpirole, the dopamine D2 receptor antagonist sulpride, or
vehicle. One day after the acquisition phase, they issued the extinction phase immediately
after one of the compounds was injected. Twenty-four hours after the extinction phase,
Ponnusamy and colleagues administered another extinction phase in which they
measured differences in the amount of freezing between the different drug conditions.
While the quinpirole animals exhibited about as much freezing as they did in the prior
extinction phase, the sulpride animals showed a significant decrease in freezing when
compared to the vehicle animals on the second extinction day. While dopamine D2
receptor agonism appears to suppress the expression of fear, dopamine D2 receptor
antagonism has been shown to facilitate fear extinction. Scibilia et al. (1992) used
autoradiographic procedures to show that sulpride primarily binds to the CeA region of
the amygdala; while dopamine D2 receptors were located in the BLA, the CeA was found
to contain a higher concentration of dopamine D2 receptors. Additionally, sulpride has
been shown to reduce freezing in a footshock-induced contextual conditioning procedure
when administered into the BLA post-acquisition (de Souza Caetano, 2013).
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The Neurotensin System and Monoamine Interactions
Neurotensin (NT) is a thirteen amino acid peptide neurotransmitter that was first
isolated from the bovine hypothalamus (Tanganelli et al., 2012). While it regulates
gastro-intestinal cellular communication, it has also been found to influence mammalian
endocrine, paracrine and nervous systems. There are three known neurotensin receptor
subtypes, neurotensin receptor type 1-3, but only neurotensin type 1 and type 2 receptors
have been linked to overt behavior in rodent models. Neurotensin type 1 receptor
(NTS1) activation has been shown to influence animal models of food intake and
psychological disorders, including anxiety, depression, and schizophrenia, while
neurotensin type 2 receptor (NTS2) activation has been given an analgesic profile
(Boules, 2013). Both of these receptor subtypes are seven transmembrane domain Gprotein coupled receptors.
NTS1 differentially activates Gi/o , Gs and Gq/11 G-protein pathways depending on
the cell type and ligand that it interacts with. There is evidence that direct interactions
exists between NTS1 agonists and G-proteins (Pelaprat, 2006). The affinity of NT for
NTS1 has been shown to decrease when Gi/o activity is disrupted by pertussis toxin
(Gailly et al., 2000). Furthermore, pertussis toxin reduces NT induced GTPγS binding for
rat NTS1 receptors, again demonstrating a preference for NT/ Gi/o interactions (Najimi et
al., 2002). While less is known about NTS2/G-protein interactions, it has been
hypothesized that NTS2 receptors also differentially activate multiple G-protein
pathways (Pelaprat, 2006).
Endogenous NT has nearly fifteen times greater affinity for NTS1 than it does for
NTS2. NTS2 was first found to be activated by the synthetic histamine H1 receptor

12

antagonist levocabastine, which has no affinity for NTS1 (Vincent et al., 1999). The
synthetic compound SR48692 has been shown to selectively antagonize NTS1 activation.
The binding sites for SR48692 overlap with NT binding sites, suggesting that SR48692
acts as a competitive antagonist for NT at NTS1 (Labbe-Jullie et al., 1998). NTS2
expressing COS cells, which are derived from monkey kidney tissue, have a ligandreceptor binding profile almost complimentary to NTS1. In this cell line, SR48692
administration at NTS2 produces intracellular Ca2+ mobilization. While NT, neuromedin
N and levocabastine do not antagonize SR48692 induced Ca2+ mobilization, they have
been shown to act as both agonists and antagonists for other SR48692 activated NTS2
second messenger pathways (Pelaprat, 2006).
NTS1 exists in the CNS on both pre- and post-synaptic neurotensinergic neurons
(Tanganelli, 2012). neurotensinergic systems have been found to co-localize with both
amino acid and monoamine neurotransmitter systems in brain regions such as the ventral
tegmental area, substantia nigra, striatum, nucleus accumbens, raphe nucleus,
hypothalamus, and amygdala (Boudin et al., 1996). This suggests that
neurotensinergic/monoaminergic interactions could be integral to the mechanisms by
which NTS1 activation facilitates behavior. While little is currently known about
neurotensinergic/noradrenergic interactions, there is interaction data concerning the other
monoamines.
Dilts et al. (1996) used both tryptophan hydroxylase and 5-hydroxytrytophan (5HTP) levels to demonstrate that NT attenuates sound stress-induced increases in 5-HT
levels. Prior to a sound stress test, rats received an i.p. injection of NSD 1015, an
aromatic amino acid decarboxylase inhibitor which prevents 5-HTP from degrading into
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5-HT, and an i.c.v. injection of NT. NT significantly reduced both tryptophan
hydroxylase, which converts tryptophan into 5-HTP, and 5-HTP levels when compared to
sham brain tissue after the sound stress test was administered. The decrease in 5-HT
levels does not imply that NT decreases serotonergic activity. Jolas and Aghajanian
(1996) demonstrated that application of NT and its 8-13 amino acid fragment produced
excitatory activity at the dorsal raphe nucleus; this increased activity was blocked by
SR48692.
NT may also be linked to serotonergic activity in the limbic system. Shugalev et
al. (2008) demonstrated that the 5-HT1A receptor agonist 8-OH-DPAT shares a profile
with NT in a passive avoidance task. When 8-OH-DPAT or NT are administered into the
rat substantia nigra, shorter latencies are observed before the animals move onto a shock
grid that has been associated with aversive shock. Inversely, both 8-OH-DPAT and NT
produce greater latencies prior to crossing when they are administered into the dorsal
cervical nucleus. The decrease in passive avoidance learning observed in animals treated
with NT in the substantia nigra coincided with increases in 5-HT and its metabolite, 5hydroxyindoleacetic acid, in their caudate nuclei. It is still not known whether these
similar behavioral profiles are representing similar physiological pathways, but there is a
high probability that both NT and 5-HT facilitate dopaminergic transmission within the
rat midbrain.
There is an abundance of direct evidence that NT and DA systems interact. Mice
that are knockouts for NTS1 show greater d-amphetamine induced locomotion than their
wild type counterparts while expressing less mRNA for the dopamine D1 receptor (Liang
et al., 2010). The decrease in dopamine D1 receptor expression coincided with a reduced
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affinity of the dopamine D2 receptor family antagonist raclopride for D2. Relationships
between midbrain dopamine D2 receptors and NTS1 expression have also been evaluated
using electrophysiological techniques. Amano et al. (2008) demonstrated that synapses
between the LA and the BLA for tissue extracted from NTS1 knockout mice were prone
to express LTP at currents that did not produce LTP in wild type synapses. They also
showed that the pharmacological blockade of NTS1 via SR48692 eliminated LTP in
knockout preparations. The dopamine D2 receptor antagonist sulpride also eliminated
LTP in NTS1 knockout brain tissue while the dopamine D2 agonist quinpirole produced
LTP for wild type preparations. These findings allude to the possibility that
neurotensinergic activity modulates dopaminergic activity, which is consistent with our
current understanding of NTS1/D2 interactions.
Fawaz et al. (2009) used a combination of electrophysiological and
pharmacological techniques to elucidate relationships between NTS1 and D2
autoreceptors on presynaptic DA neurons in the nucleus accumbens (NAc) shell. Tetanus,
or constant, stimulation at the NAc shell produces increases in extracellular DA levels.
When the selective dopamine D2 autoreceptor agonist quinpirole was applied, in vitro,
electrical stimulation-induced increases in DA were inhibited. Contrarily, both the
dopamine D2 antagonist sulpride and the NT 8-13 fragment, the active fragment,
facilitated DA release. It was theorized that the similar effects of sulpride and NT 8-13 at
electrically stimulated DA neurons are due to presynaptic dopamine D2 receptor
modulation by both sulpride and NT 8-13. The effects of NT 8-13 could be masked by
prior sulpride treatment.
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There is also evidence that NT modulates the affinity that striatal dopamine D2
receptors have for DA (von Euler & Fuxe, 1987). These NTS1/D2 interactions are shown
to take place at the presynaptic terminals of glutamate projections from the cortex to the
limbic system and at postsynaptic terminals of NAc GABA neurons, which inhibit
neurons in the ventral pallidum (Tanganelli, 1994; Ferraro et al., 2000). These
interactions also occur both pre- and post-synaptically within the basal ganglia (Antonelli
et al., 2007). NT appears to facilitate amino acid neurotransmission by antagonizing the
dopamine D2 receptor, but the glutamatergic NMDA receptor is also a candidate for
direct interactions with NT systems. Ferraro et al. (2011) have hypothesized that
increases in NT induced cortical glutamate might be a result of NT up-regulating
postsynaptic NMDA receptor activity on glutamate neurons.
There is an abundance of data suggesting that NTS1 and D2 form complexes at
plasma membranes. Using confocal microscopy techniques, Borroto-Escuela et al.
(2013) were able to visualize three different homologies of NTS1/D2 heteromers within
the HEK293T cell line. These heteromers consisted of co-localized NTS1 and D2 binding
sites. The two major homologies indentified were either at pre- or postsynaptic terminals.
There are possibly many interactions taking place between NTS1 and D2 at these
heteromers. The NTS agonist JMV-449 blocks the ability of quinpirole to activate the
dopamine D2 receptor Gi/o G-protein cascade, which eventually leads do decreased
cAMP response element-binding protein (CREB) activity at a neuron’s nucleus (BorrotoEscuela et al., 2013).
JMV-449 also facilitated quinpirole induced mitogen-activated protein kinase
(MAPK) activity. The NTS1/ Gq/11 G-protein pathway could have protein kinase C both
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desensitizing the D2 receptor and facilitating MAPK activity (Thibault et al., 2011).
Borroto-Escuela et al. (2013) proposed that a synergistic effect might occur when MAPK
activity is influenced by both the NTS1/Gq/11 and D2/Gi/o pathways. It is still uncertain
whether the reduced affinity of the dopamine D2 receptor homologies for D2 agonists is
due to cytoplasmic interactions between the receptor sites or more direct interactions at
the cell membrane. Regardless, NTS1 agonists appear to produce conformational changes
in D2 which reduces its ability to bind to both DA and synthetic D2 ligands (Koschatzky
et al., 2011). Since the effects NTS agonists are homologous to dopamine D2 receptor
antagonists and endogenous NT modulates glutamate, GABA and 5-HT transmission, the
neurotensin NTS1 receptor has become a novel target for the pharmacological treatment
of psychological disorders.

Neurotensin Type 1 Receptor Agonists in Animal Behavioral Models
NT and NT analogs produce effects in a multitude of animal models involving
rodents. In open field tasks, both NT and NT analogues produce a reduction in
movement. I.c.v. injections of NT at concentrations of 1, 5, and 10μg will produce a
decrease in locomotion at the perimeter of a novel open field, but will also increase the
time a rat spends within the center of a novel open field (Elliot et al., 1986). When
organisms stay near the center of an ‘open’ environment, they are believed to be
demonstrating anxiolytic, or anti-anxiety, behavior. NTS1 agonist-induced attenuation of
locomotor activity has also been demonstrated by the brain penetrant selective NTS1
agonist PD149163. Vadnie et al. (2014) gave systemic injections of PD149163 to
C57BL/6J mice, which exhibited hypolocomotion at doses as low as 0.1 mg/kg. While
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NTS1 agonists have been shown to reverse amphetamine-induced hyperlocomotion in
rats, Norman et al. (2008) found that after 7 days of repeated i.c.v. administration of
either NT or PD149163, the compounds would not reverse amphetamine-induced
hyperlocomotion; this means that they exhibited behavioral tolerance. Amphetamineinduced hyperlocomotion was potentiated by either NT or PD149163 administration after
21 days of repeated administration.
Neurotensinergic activity influences food intake in rats. NT administered
unilaterally at the rat paraventricular hypothalamus produces dose-dependent reductions
in food intake (Stanley et al., 1983). This reduction in food intake has been linked to
NTS1-leptin interactions. Kim et al. (2008) hypothesized that these interactions are
integral to leptin’s appetite suppressant efficacy. They found that NTS1 knockout mice
do not exhibit profound reductions in food intake after an acute 5μg i.c.v. administration
of leptin. PD149163 also demonstrates appetite suppressant effects which do not exhibit
tolerance (Feifel et al., 2010). Subcutaneously administered PD149163 suppresses
appetite in rats containing leptin and in ob/ob mice that are leptin deficient. This
demonstrates that while NTS1 activation facilitates leptin activity, the converse
relationship has not been demonstrated. The appetite suppressant effects are found to
coincide with hypothermia (Feifel et al., 2010).
CNS NT activity has been associated with antinociception in rats. On the hot plate
paradigm, i.c.v. injections of NT into the rat CeA demonstrate an ED50 at 2.4μg while
i.c.v. injections into the lateral ventricle demonstrate an ED50 of 93.2μg (Kalivas et al.,
1982). Additionally, many derivatives of the NT 8-13 fragment are effective on multiple
animal models of analgesia (Hughes et al., 2010).
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These antinociceptive effects may be mediated by interactions between NT
systems and the pariaqueductal grey (PAG). Projections from the PAG to the rostral
ventromedial medulla are potentiated when NT is administered at the PAG (Li et al.,
2001). While NT does produce antinociception, it is believed that these effects are mostly
mediated through NTS2. Intrathecal injections of levocabastine and the selective NTS2
agonist JMV-431 produce antinociception in rats after receiving chronic constriction
injury (Tetreault et al., 2013). Levocabastine and JMV-431 have also been shown to
reduce pain in the plantar-formalin injection model of nonciception (Roussy et al., 2009).
NTS1 agonists appear to influence many models of learning. Using the novel
object discrimination task, Azmi et al. (2006) showed that 3μg of PD149163 significantly
increased the time a rat spent exploring a novel object. This concentration was able to
reverse the disruptive effects of scopolamine and was blocked by the non-selective NTS
antagonist SR142948A. PD149163 has been shown to improve social discrimination in
the Brattleboro rat strain, a strain which demonstrates learning deficits in models of
schizophrenia, while also improving delaying non-match to sample performance in the
Brown Norway strain, a strain of rats exhibiting many age-related learning deficits (Feifel
et al., 2009; Keiser et al., 2014). Rowe et al. (2006) found direct associations between the
number of NT binding sites throughout the rat brain and performance in the Morris water
maze (MWM) spatial memory task. Injections of NT into the CeA reduce the escape
latency for rats navigating a MWM (Laszlo et al., 2010). This demonstrates that the CeA
NT system has a role in spatial memory. Additionally, hundred and 250ng bilateral CeA
injections of NT produce conditioned place preference in rats, an effect that is blocked by
SR48692 at the 100ng concentration (Laszlo et al., 2010).
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NTS1 activation has major implications for the treatment of psychological
disorders. Binder et al. (2002) showed that NTS1 antagonism produces a disruption in the
latent inhibition of cue conditioned foot-shock induce freezing behavior. Since latent
inhibition, or the tendency of animals to ignore initially irrelevant stimuli, disruption is a
model of learning deficits in patients with schizophrenia, NTS1 agonists are putative
treatments of psychotic disorders. PD149163 blocks the psychotic profile of the 5-HT2A
agonist DOI in the rat pre-pulse inhibition task (Feifel, Melendez & Schilling, 2003). In
the conditioned avoidance paradigm, a task designed to elucidate the sensory-gating
effects of anti-psychotic drugs, it has been demonstrated that, unlike the typical antipsychotic haloperidol, PD149163 produces a significant shift from conditioned avoidance
to conditioned escape without producing catalepsy at effective doses (Holly, Ebrecht &
Prus, 2011).
NTS1 activation has also been linked to reductions in anxiogenic behavior.
Shilling & Feifel (2008) were able to attenuate fear-potentiated startle in rats after
subcutaneous injections of 1 mg/kg PD149163. This dose did not produce significant
reductions in baseline startle. In contexts that produce mild shock, differences in freezing
can be shown between NTS1 knockout mice and their wild type counterparts (Yamada et
al., 2010). These differences, however, are masked when a greater current is applied.
Prus, Hillhouse & LaCrosse (2014) demonstrated that PD149163 produces reductions in
rat 22-kHz ultrasonic vocalizations at doses as low as 0.3 mg/kg. Tasks which measure
ultrasonic vocalization, while still rare, are reliable models of rodent affective states.
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Ultrasonic Vocalization as an Indicator of Anxiety
Rat ultrasonic vocalizations (USVs) are a product of laryngeal muscle
contractions that are mediated by the hindbrain (Brudzynski, 2009). The constant
frequency 22-kHz type calls rats produce are indicative of a ‘negative’ emotional state
while the frequency modulated 50-kHz calls are indicative of a ‘positive’ emotional state
(Brudzynski, 2013). 22-kHz calls are believed to function as alarm calls and their
emission correlates with many defensive behaviors such as conditioned freezing, staying
in the closed arms of an EPM, and the burying of aversive objects (Molewijk et al., 1995;
Borta, Wohr, & Schwarting, 2006). The 22-kHz calls are also emitted when a rat has its
attention directed towards a predator; the frequency of the call is directly proportional to
a rat’s proximity to its predator (Litvin, Blanchard, & Blanchard, 2007). This means that
22-kHz USVs might act as stimuli that predict aversive stimuli, in general. Unlike 22kHz USVs, 50-kHz USVs are emitted when a rat is undergoing appetitive behaviors such
as sexual intercourse and cocaine self-administration (Wohr & Schwarting, 2012).
It has become a well-established fact that one of the functions of these
vocalizations is communication. USVs are emitted at times when rat colonies work as a
group; that is, like a contagious behavior, the entire colony unanimously exhibits
avoidance or approach behavior (Brudzynski, 2013). This implies that USVs may act as
socially transmitted predictors for either appetitive or aversive stimuli. When prerecorded
22-kHz and 50-kHz USVs are played back to rats that are not initially producing calls,
those rats begin to produce the same calls that are emitted and acquire avoidance or
approach behavior (Sadananda, Wohr, & Schwarting, 2008). Expression of c-fos shows
that playback of 50-kHz USVs evokes activation of regions associated with positive

21

affect, such as the ventral tegmental area, while 22-kHz USVs are linked to activation of
the amygdala and PAG; which have been linked to negative affect. 50-kHz calls are
mediated by mesolimbic dopaminergic activity while 22-kHz calls are mediated by
mesolimbic cholinergic activity. All neural activity that correlates with USV production
is downstream from the rostral projections of different ventral tegmental area sub-nuclei
(Brudzynski, 2013).
22-kHz USVs appear to be indicative of anticipatory fear rather than immediate
fear responding. Jelen, Soltysik & Zagrodzka (2003) monitored 22-kHz USV emissions
in rats that were both trained under a cue that predicts a mild shock and a safety cue, that
when presented at the end of the non-safety cue, predicted that no shock would occur.
While trained rats would produce constant vocalization, the non-safety cue produced
reductions in calls while the safety cue reversed this effect. This might imply that 22-kHz
USVs are indicative of fear states that are products of a rat’s inability to predict the
occurrence of aversive stimuli within a given environment. As implied, 22-kHz USVs
can be conditioned to aversive stimuli. When lesions are made to the CeA, only
conditioned 22-kHz USV production is abolished while 22-kHz calls are produced in the
presence of an aversive stimulus (Choi & Brown, 2003). 22-kHz calls can also be used to
elucidate the aversive effects of drugs. Burgdorf et al. (2001) gave rats either lithium
chloride or vehicle prior to putting them into a distinct chamber. Rats began to produce
22-kHz USV calls in the chamber that was paired with lithium chloride without
producing calls in the chamber that was paired with vehicle.
22-kHz USV calls appear to be indicative of negative affect in contextual fear
conditioning models. Molewijk et al. (1995) generated an anxiolytic profile for a
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conditioned foot-shock induced USV paradigm. On day 1, rats were trained to produce
USVs in an operant chamber via a 7min training session which consisted of 6 pseudorandomly distributed 0.8mA shocks from the chamber’s shock-grid. These rats were then
given a pre-test session, on day 2, which consisted of them being put in the chamber for
10min while their USVs were recorded. Rats that met the baseline USV criterion were
subsequently tested, on day 3, using the same procedure as day 2 with the exception of
drug administration.
It was determined that this model is sensitive to compounds that are known to
have anxiolytic profiles. Alprazolam, a BDZ site positive modulator, SSRIs and 5-HT1A
receptor agonists reduced the number of recorded 22-kHz USV calls (Molewijk et al.,
1995). This effect was also demonstrated by the 5-HT/NA reuptake inhibitor imipramine
and α2-adrenorecptor agonists, which inhibit noradringeric activity. This paradigm is also
sensitive to the dopamine D2 receptor antagonist haloperidol, but only at doses that
disrupt motor behaviors (Molewijk et al., 1995; Prus, Hillhouse & LaCrosse, 2014). For
most compounds that produce anxiolytic effects on this USV model, they do not produce
anxiolytic effects at doses that disrupt locomotion on an open field.
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RATIONALE

Prus, Hillhouse & LaCrosse (2014) have already shown that acute administration
of the selective NTS1 agonist PD149163 attenuates 22-kHz USVs in male Wistar rats
trained under the conditioned foot-shock model used by Molewijk et al. (1995). The aim
of the current project was to extend these findings by testing the CNS effects of
PD149163 and NT in the conditioned foot-shock induced USV model. I.c.v.
administration of PD149163 determines if its effects are centrally mediated; there is a
chance that the effect that was produced by subcutaneous administration of PD149163
was a result of peripheral neurotensinergic activity only. Since the full NT peptide is too
large to pass through the blood brain barrier, the effect of subcutaneous NT has not been
tested in this USV model. I.c.v. administration of NT allows for a profiling of the USV
related anxiolytic properties of endogenous NT within the conditioned foot-shock
paradigm. Given that there are relationships between NT and monoamine systems and
that anxiety-like behavior can be influenced by NT and monoamine systems, these
findings might aid in the development of putative compounds for the pharmacological
treatment of anxiety disorders.
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METHODS

MATERIALS

Subjects
Twenty male Wistar rats where purchased for this study (Charles River
Laboratories, Portage, MI). Ten subjects were purchased for Experiment 1 while 10 were
purchased for Experiment 2. All rats were housed in an animal room that is part of
Northern Michigan University’s Neuropsychopharmacology Laboratory. This room is set
to an automatic light/dark cycle in which the lights turn on at 8:00 a.m. and turn off at
8:00 p.m., regulating their sleep cycle. Subjects were housed in individual changes and,
since their arrival; their weights were measured a few times a week. Once they reached
approximately 300 grams, they underwent a pre-training/testing procedure which would
determine their eligibility for drug testing (described below). All procedures administered
to the subjects were approved by the Institutional Animal Care and Use Committee
(IACUC) (see Appendix A).

Anesthetics/Analgesic
Pentobarbital and chloral hydrate were purchased from Sigma-Aldrich as agents
in an anesthetic solution. To create this solution, 810 mg of pentobarbital, 4.3 g of
chloral hydrate, and 2.12 mg of magnesium sulfate were dissolved in a 100 mL solution
containing 29% propylene glycol and 14% ethanol. This anesthetic was injected into the
intraperitoneal cavity prior to the surgical procedure. Penicillin G, purchased from Butler
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Schein Animal Health (Dublin, OH), was subcutaneously injected immediately after
sedation in order to reduce the likelihood of surgical or post-surgical infection.
Buprenorphine, a partial agonist at mu-opioid receptors, was used as a post-operative
analgesic; for the two days following surgery. It was administered subcutaneously every
morning and evening at a concentration of 0.05 mg/kg.

Test Compounds
PD149163 was generously provided by the NIMH Drug Repository (Bethesda,
MD) and NT was purchased from AnaSpec (Fremont, CA). For easier distribution
throughout the CNS, these compounds were prepared in a phosphate buffering solution
(PBS) that was purchased from Sigma-Aldrich (St. Louis, MO). Ten mL of 1.2 mM
calcium chloride was added to this solution in order to make it homologous to
cerebrospinal fluid. PD149163 was prepared at 0.0001, 0.001, 0.01, and 0.1μg/2μL
concentrations. NT was prepared at concentrations of 0.1, 1.0, and 10.0μg/2μL.

Surgical Equipment
Twenty-six gage guide cannulae (C315G-SPC) were purchased from PlasticsOne
(Roanoke, VA); extending 3 mm below the pedestal. A stereotaxic surgical device was
used to position anesthetized subjects during the surgery (Stoelting Co., Wood Dale, IL).
An autoclave made by Inotech (Dietikon, CH) was used to sterilize all surgical tools
immediately prior to surgery and an electric razor was used to remove hair from the
surgical zone before operating. A dental drill was used to produce three 1 mm diameter
holes in the skull after surgical scissors and cotton swabs were used to remove dermal
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and periosteum tissue from the surgical zone. Two 1.2 by 3 mm2 screws and acrylic
cement were used to mount the cannulae to the skull. After surgery, heated pads and
towels were used to prevent hypothermia. Thirty-three gage dummy cannulae (C315DCSPC) were purchased from PlasticsOne for placement into guide cannulae between
testing sessions.

Microinjection Equipment
Thirty-three gage injection cannulae (C315I-SPC) were purchased from
PlasticsOne (Roanoke, VA) for placement inside the guide cannula during the i.c.v.
injection procedure. These cannulae extended 2 mm passed the guide cannulae once
inserted. Teflon tubing, with an interior diameter of 0.12 mm, (Bioanalytical Systems,
Inc., Lafayette, IN) was used to transport injected fluid from a syringe pump to an
injection cannula. The syringe pump (MD-1001) (Bioanalytical Systems, Inc.) pushed
solution out of a 1 mL syringe, through the Teflon tubing, at a rate of 2μL per minute

USV Apparatus
A commercially built 30.5 by 24.1 by 21.0 cm ultrasonic vocalization
chamber was used for all experimental procedures (Med Associates, St. Albans, VT) (see
Appendix B). This chamber is equipped with a USV detector (ANL-937-1) that records
USVs within a 20-30 kHz frequency band. It binned USVs produced at each frequency
throughout a spectrum of sound pressure. Based on previous literature (Brudzynksi,
2013), USVs recorded under 30 dB or USVs that were less than 0.3 seconds in duration
were excluded from analysis. An electrical amplifier was used to run a 0.8 mA current
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throughout the chamber’s grid floor. These mild shocks were 8 seconds in duration. Two
signal light were used to illuminated the chamber during the entirety of all training and
testing sessions. All shocks, lighting and USV recording was controlled using MED PC 4
software (Med Associates, St. Albans, VT).

Open Field Apparatus
Subjects were tested on a circular open field approximately 117.5 cm in diameter.
This open field doubles as a Barnes maze, so there were 12 open holes lining the
perimeter of the field placed at equidistant intervals (see Appendix B). The Barnes maze
escape box was removed while the Barnes maze was used as an open field. Bright lights
and a camera (Panasonic, Newark, NJ) were mounted above the open field. Locomotion
was analyzed using Ethovision 7 video tracking software (Noldus Information
Technology, Wageningen, NL).

PROCEDURES

Outline of USV Procedure
The USV procedure is differentiated into two distinct phases. The first phase is a
pre-training/testing procedure followed by a stereotaxic surgical procedure, which
prepares the subjects for i.c.v. injection. The second phase occurs one week after the
surgical procedure and consists of retraining followed by drug testing. The drug testing
procedure involves the recording of USVs after i.c.v. injections of NTS agonists. This
USV procedure is a form of contextual fear-conditioning which has its subjects associate
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foot-shocks with the chamber they are shocked in. This makes them produce conditioned
USVs, which are used as a measure of anxiety-like behavior.

Pre-operative Training and Testing
The pre-training/testing procedures were modified from those described by
Molewijk et al. (1995). Pre-training/testing consisted of three consecutive days. On days
1 and 2, each rat was put in a shock chamber and was administered 6 pseudo-randomly
distributed shocks within a 7 minute session. On day 3, each rat was put in the shockassociated chamber and given a 2 minute ‘reminder’ session which involved the
administration of 1 shock towards the middle of the session. Thirty minutes later, 22-kHz
USVs were recorded in the shock-associated chamber over a 10 minute testing session;
no shock was implemented during the testing session. Any subjects that produced fewer
than 80 calls during the pre-testing session were excluded from the surgical procedure
and further testing.

Surgical Procedure
Anesthetized rats had their heads shaved and were mounted to the ear and incisor
bars of a stereotaxic surgical device. The dermal layer of tissue surrounding the top of
the skull was removed using stainless steel surgical scissors. Smaller scissors and cotton
swabs were used to cut and remove the remaining periosteum that surrounded the skull.
Once the skull was exposed, 95% ethanol was applied, using a cotton swab, to all regions
of the skull. The location of bregma was then determined.
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A hole was drilled at: Anterior/Posterior = -1.0 mm, Medial/Lateral = +2.0 mm
from bregma. The guide cannula was lowered 2 mm below the hole. During testing, an
injection cannula would be inserted that projects 2 mm beyond the tip of the guide
cannula and into the lateral ventricle (stereotaxic coordinates were provided by the Rat
Brain Atlas, Paxinos and Watson, 1986). Two more holes were drilled into the skull and
screws were used to attach acrylic cement to the skull.

USV Testing Procedure
The testing procedure was conducted over a course of 6 consecutive days.
Day one consisted of the training session mentioned in above sections. On day two, the
subjects were placed in the experimental chamber for 2 minutes, receiving one shock
(i.e., a reminder shock) after approximately the first minute. After the ‘reminder’ shock
trial, they were taken out of the box and given the i.c.v. injection.
Prior to perfusion, the dummy cannula was removed and was replaced by an
injection cannula. Once the injector was secure, the syringe pump was turned on and a 2
minute timer was started. The syringe pump pushes compounds into the brain at 2µL per
minute. The pump was turned off after the first minute, having allowed 2μL of solution to
enter the lateral ventricle. The injection cannula was left in the injection site for an
additional minute to allow for any remaining solution to disperse from the tip of the
injector. The animal was then placed back into its home cage.
Thirty minutes after injection, the subject was put back into the chamber for a 10
minute test trial. In Experiment 1, the day 2 procedure was continued for 4 consecutive
days. On day 2, PBS was administered to all subjects for the first baseline measure. On
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days 3, 4, and 5, PD149163 was given to all subjects at 0.1, 1.0, and 10ng amounts,
respectively. The 6th day was a second baseline testing day, which consisted of the same
set of procedures as day 2. In Experiment 2, all procedures were identical to Experiment
1 with the exception that, instead of PD149163, NT was administered on days 3, 4, and 5,
at 0.1, 1.0, and 10.0μg, respectively. Cross testing was also done after the second baseline
test session: in Experiment 1, 10μg of NT was injected on day 7, and in Experiment 2,
10ng of PD149163, PBS and 100ng of PD149163 were injected on days 7, 8, and 9,
respectively.

Outline of Locomotor Procedure
Subjects in Experiment 2 were tested on an illuminated open field after PD149163
cross-confirmation data was collected.

Locomotion Testing Procedure
All subjects were habituated to the open field over a 10 minute session one day
prior to the first testing session. On the first testing day, subjects were monitored on the
open field for 10 min after a PBS injection, which occurred 30 min prior to testing. Day 2
only differed from Day 1 in that 0.1μg of PD149163 was administered instead of PBS.
The procedure on Day 3 was identical to the Day 1 procedure. All microinjection
procedures were identical to the protocol described in the USV experiments.

HISTOLOGY
To determine probe placement accuracy, rats were euthanized with at least 100
mg/kg pentobarbital (i.p.). A small amount of ink was inserted into the injection site
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using an injection cannula, Teflon tubing and a 1 mL syringe. This treatment makes it
easier assess cannulation accuracy. The subject’s brains were subsequently extracted and
placed into scintillation vials filled with formalin. After 48 hours of sitting in formalin,
the brains were sectioned to verify the placement of injection cannulae. Subjects with
inaccurate cannula placement were excluded from the data analysis (see Appendix B).

DATA ANALYSIS
During all 10 minute USV recording sessions, the number of 22-kHz calls emitted
between 0.3 and 4 seconds in duration were recorded in MED PC 4. Descriptive data was
expressed using mean number of calls per session +/- standard error of the mean. First
and second baseline testing values were compared using a paired t-test and the average
baseline was calculated. Analysis of Variance (ANOVA) and Dunnett’s multiple
comparison tests were used to test for significant differences in the number of USVs
between average baseline and treatment conditions.
During all 10 minute locomotion recording sessions, the distance traveled was
measured in centimeters. Descriptive data was expressed using the mean distance
traveled per session +/- standard error of the mean. First and second baseline testing
values were compared using a paired samples t-test and the mean baseline was calculated.
A paired samples t-test was used to test for significant differences in the distance traveled
between the mean baseline and treatment condition. Statistical analysis of all
experimental data was run using Graph Pad Prism 6 software (GraphPad Software, Inc.,
La Jolla, CA).
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RESULTS

USV PROCEDURE

Experiment 1
Figure 1 represents a comparison of the mean values for first and second PBS
baselines in Experiment 1. There was no statistically significant difference between the
first and second baseline values, t = 0.12, p > 0.05. Figure 2 represents a comparison of
the mean values of the average baseline, which was calculated from the first and second
baselines, and three PD149163 treatment conditions: 0.1, 1.0, & 10.0ng. PD149163
administration produced a decrease in USV production, F(3,6) = 17.33, p < 0.01. Ten ng
of PD149163 significantly reduced the number of vocalizations when compared to
vehicle, p < 0.001. Figure 3 represents a comparison of mean value for the second
baseline and the mean number of vocalizations after administration of NT. NT produced
a significant decrease in USVs at the 10μg concentration, t = 3.29, p < 0.05.

Experiment 2
Figure 4 represents a comparison of the mean values for first and second PBS
baselines in Experiment 2. There was no statistically significant difference between the
first and second baseline values, t = 0.95, p > 0.05. Figure 5 represents a comparison of
the mean values of the average baseline, which was calculated from the first and second
baselines, and three NT treatment conditions: 0.1, 1.0, & 10.0μg. NT administration
produced a decrease in USV production, F(3,4) = 8.20, p < 0.05. Ten µg of NT
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significantly reduced the number of USVs when compared to vehicle, p < 0.05. Figure 6
represents a comparison between the mean values of a third baseline, 10ng of PD149163,
and 100ng of PD149163. There was a statistically significant decrease in USVs produced
by PD149163, F(2,3) = 7.39, p < 0.05. PD149163 produced a significant decrease in
vocalizations at the 100ng concentration, p < 0.05.

LOCOMOTOR PROCEDURE
Figure 7 represents a comparison of the mean values for first and second PBS
baseline distances traveled. There was a statistically significant difference between the
first and second baseline distances, t = 6.05, p < 0.01. There was a significantly shorter
distance traveled during the second baseline. Figure 8 represents a comparison of the
mean values of the average baseline distance traveled and a 100ng PD149163 treatment
condition. There was no statistical difference between the average baseline and 100ng
PD149163 conditions, t = 0.03, p > 0.05.
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Figure 1: Experiment 1: First and Second PBS Baseline Comparison
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Figure 1 represents a comparison of USV production for the 1st and 2nd PBS baselines in
Experiment 1. USV calls refer to the number of 22 kHz calls recorded during the 10 min
testing session. 1st and 2nd refer to the assessments before and after testing PD149163.
Data are shown as means (+/- standard error of the mean). N = 7
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Figure 2: Experiment 1: PD149163 Treatment Curve
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Figure 2 represents a comparison of USV production between the average baseline,
which was calculated from the 1st and 2nd PBS baselines, and three PD149163 treatment
conditions: 0.1, 1.0, & 10.0ng. ***p < 0.001 versus vehicle. VEH = vehicle (PBS). Data
are shown as means (+/- standard error of the mean). N = 7
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Figure 3: Experiment 1: NT Cross-testing
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Figure 3 represents a comparison of USV production for the 2nd baseline and 10µg NT.
*p<0.05 versus vehicle. VEH = vehicle (PBS). Data are shown as means (+/- standard
error of the mean). N = 7
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Figure 4: Experiment 2: First and Second PBS Baseline Comparison
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Figure 4 represents a comparison of USV production for the 1st and 2nd PBS baselines in
Experiment 2.

1st and 2nd refer to the assessments before and after testing NT. Data are

shown as means (+/- standard error of the mean). N = 5
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Figure 5: Experiment 2: NT Treatment Curve
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Figure 5 represents a comparison of USV production between the average baseline,
which was calculated from the 1st and 2nd PBS baselines, and three NT treatment
conditions: 0.1, 1.0, & 10.0µg. *p < 0.05 versus vehicle. VEH = vehicle (PBS). Data are
shown as means (+/- standard error of the mean). N = 5
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Figure 6: Experiment 2: PD149163 Cross-testing
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Figure 6 represents a comparison of USV production for the 3rd baseline, 10ng and
100ng PD149163. *p<0.05 versus vehicle. VEH = vehicle (PBS). Data are shown as
means (+/- standard error of the mean). N = 4
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Figure 7: Open Field Experiment: First and Second PBS Baseline Comparison
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Figure 7 represents a comparison of distance traveled for the 1st and 2nd PBS baselines in
the open field experiment. There was a significantly shorter distance traveled during the
second baseline. **p < 0.01 versus baseline. Data are shown as means (+/- standard error
of the mean). N = 4
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Figure 8: Open Field Experiment: PD149163 Treatment
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Figure 8 represents a comparison of distance traveled for the average baseline distance
traveled and a 100ng PD149163 treatment condition. VEH = vehicle (PBS). Data are
shown as means (+/- standard error of the mean). N = 4
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DISSCUSION

Ten and 100 ng concentrations of PD149163 produced significant reductions in
22-kHz USV calls in the conditioned foot-shock paradigm. This is the first time the
intracranial effects of PD149163 in this USV model have been reported. These findings
extend the findings of Prus, Hillhouse, & LaCrosse (2014), who demonstrated that
subcutaneous injections of PD149163 can attenuate USV calls. The current project shows
that central NTS1 activation might be a primary mediator during the effects demonstrated
by systemic administration of PD149163. The maximum efficacy of PD149163 between
systemic and intracerebroventricular administration methods does not differ; both
administration methods produce robust effects at larger concentrations. The treatment
curve illustrated by Figure 2 is similar in form to dose-response curves produced by
systemic administration of PD149163 using the USV paradigm (Prus, Hillhouse &
LaCrosse, 2014). These graphs suggest that PD149163 administration may produce a
narrow range of concentration-dependent changes in USV production, although a
monotonic curve might have been produced if a half-log concentration was also
administered (i.e. 3.2 ng PD149163).
Ten µg of neurotensin (NT) reduced USV production in this USV model. This
was the first time NT has been tested in this paradigm. The intracerebroventricular
injection method was required to test the potential effects of NT; large peptides, such as
NT, cannot pass through the blood brain barrier. While NT did not produce effects that
were as profound as the effects demonstrated by PD149163 (Figures 2 and 5), the effect
demonstrated by NT suggests that the effects of PD149163 are mediated by neurotensin
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receptor activation. The brain neurotensin system may have specific relationships with
brain mechanisms associated with conditioned 22-kHz USV production. Likewise, there
could be relationships between brain neurotensin and general 22-kHz USV production.
Since a microdialysis procedure has demonstrated that NT administration increases
prefrontal cortex acetylcholine levels, there is a low likelihood that NT administration
decreases a rat’s ‘ability’ to produce USVs (Petkova-Kirova et al., 2008). The production
of 22-kHz USVs is, in part, mediated by cholinergic projections from the basal forebrain
to the prefrontal cortex (Brudzynski, 2009).
Cross-testing was implemented in Experiments 1 and 2. Subjects in Experiment 1
demonstrated an effect on the USV task at 10µg NT while having a history of PD149163
exposure (Figure 3). This effect was similar to the effect of 10µg of NT in Experiment 2.
Subjects in Experiment 2 demonstrated an effect on the USV task at not 10ng, but 100ng,
while having a history of NT exposure (Figure 6). The effect of 100ng of PD149163 in
Experiment 2 was similar to the effect of 10ng of PD149163 in Experiment 1. The crosstesting demonstrated similar results between Experiments 1 and 2.
Experiments 1 and 2 demonstrated that PD149163 administration has a 100-1000
fold greater potency than NT in the conditioned foot-shock induced USV paradigm. This
difference in potency cannot be explained by merely accounting for the respective
affinities of PD149163 and NT for the NTS1 receptor. NT has been demonstrated to have
affinity for NTS1 of Ki = 0.25 nM in mouse brain tissue (Pettibone et al., 2002), while
Petrie et al. (2004) found that PD149163 has an affinity for NTS1 of Ki = 159 nM in rat
brain tissue (see Petrie et al. (2004) for a table illustrating PD149163’s highly selective
binding assay). The difference in NTS1 affinity could account for differential efficacy,
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but one must be skeptical about making comparisons across species and laboratories. A
difference in receptor selectivity could also account for differential efficacy. PD149163
only activates the NTS1 receptor while NT activates NTS1 and can act as an antagonist at
NTS2 (Pelaprat, 2006). As described in the introduction, there is a possibility that NT
analogs, such as PD149163, and endogenous NT have differing affinities for NTS1coupled G-proteins. This means that PD149163 and neurotensin could be activating
distinct second messenger systems within NTS1 expressing neurons. Skrzydelski et al.
(2003) found evidence that while NT can activate Gq/11, Gs and Gi/o pathways, the NT 813 analog EISAI-1 orientates the receptor towards its C-terminus, EISAI-1 bound NTS1
then preferring the Gs and Gi/o, but not Gq/11, pathways; Gq/11 is bound to the third
intracellular loop of NTS1.
One hundred ng of administered PD149163 did not reduce locomotion on a
brightly illuminated Barnes maze/open field. This was demonstrated in the same subjects
that exhibited a significant reduction in 22-kHz USVs at 100ng of administered
PD149163. This suggests that the reduction in USVs produced by the 100ng
concentration is not due to a non-specific reduction in bodily movement. In the Azmi et
al. (2006) novel object discrimination experiment mentioned in the introduction, 3µg of
PD149163 in the lateral ventricle did not produce an overall reduction in rat exploratory
behavior. Vadnie et al. (2014) and Prus et al. (unpublished) have shown that mice and
rats, respectively, produce reductions in locomotion after systemic administration of
PD149163. Rats will demonstrate a reduction in locomotion on a brightly illuminated
open field 30 min after systemic administration of not 0.1, but 1.0 mg/kg, of PD149163
(Prus et al., unpublished). Systemic administration of PD149163 at 0.1 mg/kg is sub-
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effective in the USV preparation while 1.0 mg/kg produces a profound effect (Prus,
Hillhouse & LaCrosse, 2014). Additionally, the reduction in rat fear-potentiated startle
that was observed at a 1.0 mg/kg dose of PD149163 in Shilling & Feifel (2008) coincided
with a reduction in baseline startle, suggesting that the drug effect in the fear-potentiated
startle treatment may have been influenced by a general disruption of behavior. The
discrepancies between systemic and i.c.v. motor data suggests that the general reduction
in behavior observed after systemic administration of PD149163 is primarily influenced
by the PNS.
It can be argued that this USV model used presents effects that are non-specific to
anxiolytic-like behavior, but it is inarguably a more specific measure than the traditional
quantification of ‘freezing’. Freezing is a behavior that, by its general definition, is
susceptible to drug-induced response inhibition. McNish, Gewirtz & Davis (1997)
defined freezing as ‘the mean activity before training minus the mean activity after
training’. This notion of ‘activity’ is vague and can be though equivocal to locomotion.
Atsak et al. (2011) explicitly defines freezing in terms of locomotion: ‘locomotor activity
of witnesses (subjects) is sampled as 5 minute time-bins and the percentage change in
locomotion was calculated by subtracting the locomotor activity measured in the first 5
minutes (taken as a baseline) from the locomotor activity sampled in the subsequent 5
minute time-bins’.
While tasks that measure freezing should not be discredited, measuring 22-kHz
ultrasonic vocalizations allows for a more precise accurate quantification of fear-related
behavior. The measurement of discrete 22-kHz ultrasonic vocalizations, exhibiting a set
of identifiable acoustic parameters (Brudzynski, 2013), does not produce the ambiguity
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that freezing measurements produce. There also exist discrepancies between the methods
of observing freezing between laboratories. In Atsak et al. (2011), Noldus Ethovision
software was used to analyze freezing while spectators looking at surveillance footage
scored freezing in McNish, Gewirtz & Davis (1997). USVs within the 18-32 kHz
frequency band have not been associated with any behaviors that are non-defensive while
‘no-locomotion’ can be as indicative of sedation as it is defensive, or fear-induced, states
in rodent models.
Alternatively, a model of conditioned-fear that avoids the issue of non-specific
reductions in responding is the conditioned emotional response (CER) task. This task
measures increased responding, compared to vehicle, in the presence of a conditioned
aversive stimulus as indicative of an anxiolytic effect. Future evaluation of neurotensin
agonists using the CER task might better elucidate the anxiolytic profile of the
neurotenisn system, but as stated in the introduction, Neurotensinergic compounds
produce appetite suppression. This means that the reinforcer used in the CER task might
have to be a reinforcer other than food. so it Before the anxiolytic-like effects of NTS1
agonists are fully allocated to NTS1 activation, more NTS1 agonists as well as selective
NTS2 and NTS3 agonists need to have their putative anxiolytic properties evaluated
using animal models of anxiety. Furthermore, NTS antagonists, both selective and nonselective, need to be tested in conjunction with NTS agonists to determine if the actions
of these Neurotensinergic compounds are mediated through a Neurotensinergic system.
The brain neurotensin system is a potential target for the treatment of anxiety-related
disorders.
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